If it were not for bad news, the spinal muscular atrophy (SMA) community in Canada would have no news at all. At least in the past couple of months. First, the Good News Last summer, the situation was so promising—that was when the drug Spinraza (nusinersen) was approved by Health Canada for all 5q-SMA patients…
Cure SMA Canada urges timely, committed negotiations to provide coverage of first-ever and life-saving treatment for debilitating childhood disease. Cure SMA Canada, on behalf of Canadians diagnosed with Spinal Muscular Atrophy (SMA), our patient community and its supporters, is urging the provinces to come together and find a way to make Spinraza, the first-ever and…
Clinical Trials Clinical trials test drug candidates for safety and effectiveness. Clinical Trial Basics A clinical trial, also called an interventional study, tests new drugs and treatments. It can also test new applications for approved drugs or treatments (for example, using drugs in different combinations or for different diseases). This is different from an…
The Cure SMA drug pipeline is one of the primary ways we evaluate the success of our research program. The pipeline identifies the major drug programs in development, and tracks their progress from basic research through clinical trials Key Measurements The pipeline measures the progress of our research in two key ways. First, by tracking…
BIOGEN RESPONDS TO COVERAGE RECOMMENDATION BY THE CANADIAN DRUG EXPERT COMMITTEE (CDEC) FOR SPINRAZA, THE ONLY TREATMENT APPROVED FOR TREATMENT OF 5Q SPINAL MUSCULAR ATROPHY (SMA) Ottawa – December 22, 2017 – Today the Canadian Drug Expert Committee (CDEC) made public its recommendation to the Common Drug Review (CDR) participating drug plans to reimburse SPINRAZA…
Dear members of the SMA community, In response to your request for information, we would like to provide you with an update on Biogen’s SMA360 Canada Patient Support Program and the next steps following Health Canada’s approval of SPINRAZA™ (nusinersen). The SMA360 Canada Patient Support Program has been developed to be available for patients and…
We have completed our submission in to CADTH! Thanks to everyone’s support and heartfelt responses, we feel we have a very strong message to the drug review committee expressing the needs of the entire SMA committee for effective treatment and the benefits of Spinraza to improve the lives of all persons and families affected by…
Cure SMA Canada is very happy to announce the approval of nusinersen/spinraza from Health Canada. We are very excited to confirm the approval for treatment for all types of SMA in Canada. We will be communicating with the Canadian sma community our next steps as we move forth into the funding approval process to CADTH’s…
June 4, 2017 Dear members of the SMA community, In response to your request for information, we are delighted to inform you that on June 1 2017 Biogen announced that the European Commission (EC) granted a marketing authorization for SPINRAZA® (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA) which is the most common…